MI-LINEAGE-LOGISTICS-LLC
11.1.2022 08:03:03 CET | Business Wire | Press release
Lineage Logistics, LLC (“Lineage” or the “Company”), one of the world’s leading temperature-controlled industrial REIT and logistics solutions providers, today announced the acquisitions of Van Tuyl Logistics, H&S Coldstores and Frigocare Rotterdam BV. These strategic transactions will strengthen Lineage’s portfolio of end-to-end logistics solutions in the region and grow Lineage’s presence in the Netherlands by more than 250,000 cubic metres of capacity.
Based in Gameren, Van Tuyl Logistics is a Dutch provider of temperature-controlled logistics that specialises in refrigerated and frozen transport. Van Tuyl employs a modern fleet of 60 trucks and 90 trailers with a self-owned repair station, in addition to warehousing services for 30,000 pallet spaces at different temperatures and a real estate holding division.
“We are pleased to welcome Van Tuyl Logistics into the One Lineage Family as we continue to build momentum and further expand our European operations,” said Harld Peters, Senior Vice President, Europe at Lineage. “The Netherlands remains a critical hub for the food cold chain within the European market, given its central location and accessibility to key seaports and inland terminals. Accordingly, the addition of Van Tuyl will help Lineage to connect more points across our customers’ extended supply chains.”
“We know that Lineage is the right partner for the next stage in our company’s history and in our ambition to reimagine the journey of food,” said Richard van Tuijl, General Director of Van Tuyl Logistics. “Our end-to-end solutions complement Lineage’s strong and growing presence in Europe, and we are confident that our customers will continue to be well-served as we combine our logistics and cold storage operations.”
Lineage also acquired Dutch provider H&S Coldstores and its logistics forwarding business from the H&S Group, Europe’s largest intermodal Liquid Food operator.
Headquartered in Beneden-Leeuwen, H&S Coldstores provides end-to-end juice supply chain services, including transport, warehousing, customs, production, processing, laboratory testing, and packaging solutions. The logistics forwarding business from H&S Group also offers a pan-European network of more than 250 privately owned and subcontracted vehicles as well as more than 1,500 tank units for the liquid foodstuff industry.
In total, this acquisition will add a capacity of 48,000 tonnes to Lineage’s footprint in Europe. The H&S Coldstores facilities in Elst and Tiel will be moved to a new location in a newly built facility, closer to other existing facilities in Beneden-Leeuwen. This new cold store near the port of Rotterdam will be operational by mid-2022. This new facility complies with the highest LEED/BREEAM status and will make use of solar energy.
“H&S Coldstores is another fantastic example of our continued investment in the Netherlands,” said Peters of Lineage. “In particular, their differentiated juice-blending services greatly complement our existing capabilities via our recent acquisition of Kloosterboer, and will further diversify our business offering across the cold chain.”
Finally, Lineage also announced today the acquisition of the Dutch facilities of Frigocare Rotterdam BV, a company specialized in handling imports of frozen fish mainly from the North Atlantic and Asia to the Port of Rotterdam. The facility is located near an existing Lineage facility in the same harbour and will add 15,000 pallet positions in its 20,000 square metre warehouses to Lineage’s operations in Rotterdam.
Financial terms of the transactions were not disclosed.
About Lineage Logistics
Lineage Logistics is one of the leading temperature-controlled industrial REIT and logistics solutions providers worldwide. It has a global network of over 400 strategically located facilities totaling over 2 billion cubic feet of capacity which spans 19 countries across North America, Europe and Asia-Pacific. Lineage’s industry-leading expertise in end-to-end logistical solutions, its unrivaled real estate network, and development and deployment of innovative technology help increase distribution efficiency, advance sustainability, minimize supply chain waste, and most importantly, as a Visionary Partner of Feeding America, help feed the world. In recognition of the company’s leading innovations and sustainability initiatives, Lineage was listed as No. 17 in the 2021 CNBC Disruptor 50 list, the No 1. Data Science company, and 23rd overall, on Fast Company’s 2019 list of The World’s Most Innovative Companies, in addition to being included on Fortune’s Change The World list in 2020. (www.lineagelogistics.com )
About Van Tuyl Logistics
Van Tuyl Logistics is a Dutch cold chain logistics company, active in The Netherlands since its inception in 1983. The company specialises in refrigerated and frozen transport of fresh produce and other foodstuffs. Aside from its transport activities, Van Tuyl Logistics also provides storage solutions via their cold storage facility, located in Gameren, The Netherlands.
About H&S Group
H&S Group is Europe’s largest intermodal Liquid Food operator. The company is headquartered in Barneveld, The Netherlands and provides end-to-end supply chain services. H&S Group also offers a pan-European network of more than 250 privately owned and subcontracted vehicles, and more than 1,500 tank units for the liquid foodstuff industry. H&S Coldstores owns three facilities in Tiel, Beneden-Leeuwen and Elst, where it provides the following services: transport, warehousing, customs, production, processing, laboratory testing, and packaging solutions.
About Frigocare Rotterdam
Frigocare Rotterdam BV is a cold store company specialised in food logistics, specifically handling frozen fish from the North Atlantic and Asia to the port of Rotterdam, The Netherlands. The company provides the following services aside from storage: container reception, border inspection, sorting, palletizing, (re)packing and (un)loading of various delicate cargo, mostly seafood, under EU-license.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220110006028/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release
Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
